» Articles » PMID: 29264225

The Influence of Asymptomatic Inflammatory Prostatitis on the Onset and Progression of Lower Urinary Tract Symptoms in Men with Histologic Benign Prostatic Hyperplasia

Overview
Journal Asian J Urol
Specialty Urology
Date 2017 Dec 22
PMID 29264225
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Benign prostatic hyperplasia (BPH) is a condition that greatly affects the quality of life of middle-aged and elderly men. Histopathologically, hyperplastic changes frequently occur in the prostate tissue of elderly men, the incidence of which has been reported to reach approximately 80% in men in their 70s. In clinical practice, approximately 25% of men with histologic BPH are assumed to experience lower urinary tract symptoms (LUTS) and receive some kind of treatment. In other words, there are some men with histologic BPH who do not exhibit LUTS. For that reason, many factors, such as the change in hormonal environment, the immune or autoimmune response, the alteration of gene expression, and so on, are thought to affect the onset and progression of LUTS in men with histologic BPH. One such factor that has long drawn attention is the presence of asymptomatic histological inflammation, which very often accompanies symptomatic BPH. Recent studies have suggested that asymptomatic histological inflammation causes repeated destruction, healing, and regeneration of the prostate tissue, leading to the enlargement of prostatic nodules, while at the same time causing stromal tissue-predominant remodeling of the prostate tissue, which can increase urination resistance and result in the condition changing from asymptomatic BPH to symptomatic BPH. In future, the biomolecular clarification of the significance of asymptomatic histological inflammation in the prostate tissue could help develop new treatment strategies for BPH accompanied by LUTS.

Citing Articles

Tissue immunoexpression of IL-6 and IL-18 in aging men with BPH and MetS and their relationship with lipid parameters and gut microbiota-derived short chain fatty acids.

Ratajczak W, Laszczynska M, Ryl A, Dolegowska B, Sipak O, Stachowska E Aging (Albany NY). 2023; 15(20):10875-10896.

PMID: 37847180 PMC: 10637784. DOI: 10.18632/aging.205091.


The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer.

Oseni S, Naar C, Pavlovic M, Asghar W, Hartmann J, Fields G Cancers (Basel). 2023; 15(12).

PMID: 37370720 PMC: 10296711. DOI: 10.3390/cancers15123110.


Prostatic Therapeutic Efficacy of LENILUTS, a Novel Formulation with Multi-Active Principles.

Tedesco E, Benetti F, Castelli S, Fratter A Pharmaceutics. 2022; 14(9).

PMID: 36145614 PMC: 9506015. DOI: 10.3390/pharmaceutics14091866.


Applications of Vertebrate Models in Studying Prostatitis and Inflammation-Associated Prostatic Diseases.

Bleeker J, Wang Z Front Mol Biosci. 2022; 9:898871.

PMID: 35865005 PMC: 9294738. DOI: 10.3389/fmolb.2022.898871.


High degree of prostate related LUTS in a prospective cross-sectional community study in Ghana (Mamprobi).

Asare G, Sule D, Oblitey J, Ntiforo R, Asiedu B, Amoah B Heliyon. 2021; 7(11):e08391.

PMID: 34825094 PMC: 8605080. DOI: 10.1016/j.heliyon.2021.e08391.


References
1.
Homma Y, Araki I, Igawa Y, Ozono S, Gotoh M, Yamanishi T . Clinical guideline for male lower urinary tract symptoms. Int J Urol. 2009; 16(10):775-90. DOI: 10.1111/j.1442-2042.2009.02369.x. View

2.
Vignozzi L, Morelli A, Corona G, Sebastianelli A, Serni S, Gacci M . Testosterone protects the lower urinary tract from metabolic syndrome-induced alterations. Horm Mol Biol Clin Investig. 2014; 11(2):329-37. DOI: 10.1515/hmbci-2012-0029. View

3.
Taniguchi S, Taoka R, Inui M, Sugimoto M, Kakehi Y . Influence of inflammation and aging on macrophage inhibitory cytokine-1 gene expression in rat ventral prostate. Urology. 2008; 73(2):410-4. DOI: 10.1016/j.urology.2008.07.034. View

4.
Vignozzi L, Gacci M, Cellai I, Santi R, Corona G, Morelli A . Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate. 2013; 73(8):789-800. DOI: 10.1002/pros.22623. View

5.
Paralkar V, Vail A, Grasser W, Brown T, Xu H, Vukicevic S . Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem. 1998; 273(22):13760-7. DOI: 10.1074/jbc.273.22.13760. View